Surgical parameters, VEGF levels, tumor markers [matrix metalloproteinase 9 (MMP9), stromal cell-derived factor-1a (SDF-1a), and carcinoembryonic antigen (CEA)], survival rates, and incidence of complications were compared between the two groups. The gene discussed is CXCL12; the disease is neoplasm.